Potential of Xeloda® in Colorectal Cancer and Other Solid Tumors

Publisher： Karger

E-ISSN： 1423-0232|57|1|27-32

ISSN： 0030-2414

Source： Oncology, Vol.57, Iss.1, 1999-07, pp. : 27-32

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dose Escalation Study on Oxaliplatin and Capecitabine (Xeloda) in Patients with Advanced Solid Tumors

By  

Oncology, Vol. 66, Iss. 4, 2004-06 ,pp. : 253-259

Karger

Access to resources Recommend Favorite

A Dose Escalation Study of Pegylated Liposomal Doxorubicin (Caelyx) in Combination with Capecitabine (Xeloda) in Patients with Refractory Solid Tumors

By  

Oncology, Vol. 69, Iss. 6, 2006-02 ,pp. : 463-469

Karger

Access to resources Recommend Favorite

Xeloda® in the Treatment of Metastatic Breast Cancer

By  

Oncology, Vol. 57, Iss. 1, 1999-07 ,pp. : 16-20

Karger

Access to resources Recommend Favorite

Clinical Outcome of Topotecan: New Strategies Play an Important Role in the Treatment of Lung Cancer, Other Solid Tumors, and Hemoblastosis

By  

Oncology Research and Treatment, Vol. 21, Iss. 4, 1999-01 ,pp. : 1-1

Karger

Access to resources Recommend Favorite

Cancer Stem Cells in Solid Tumors

By  

Oncology Research and Treatment, Vol. 32, Iss. 10, 2009-09 ,pp. : 605-609

Karger

Access to resources Recommend Favorite